VKTX: Results from Phase 2 Trial of VK5211 in Hip Fracture in mid-2017
Yahoo! Finance USA,
By David Bautz, PhD NASDAQ:VKTX Business Update Viking Therapeutics, Inc. ( VKTX) is a biopharmaceutical company developing…
By David Bautz, PhD NASDAQ:VKTX Business Update Viking Therapeutics, Inc. ( VKTX) is a biopharmaceutical company developing…
By David Bautz, PhD NASDAQ:VKTX Business Update Viking Therapeutics, Inc. (VKTX) is a biopharmaceutical company developing…
VK2809 Update VK2809 (formerly known as MB07811) is a novel, orally available, selective thyroid hormone receptor (TR) agonist…
By David Bautz, PhD NASDAQ:VKTX Business Update VK5211 Update Viking’s (VKTX) lead drug candidate is VK5211, a third-generation…
By 1 hour ago By David Bautz, PhD NASDAQ:VKTX Financial Update On March 8, 2016, Viking Therapeutics, Inc.